Beam Therapeutics Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0.49Mn |
Net Profits | $-122.68Mn |
Net Profit Margins | -25036.33% |
Beam Therapeutics Inc. Common Stock’s revenue fell -94.21% since last year same period to $0.49Mn in the Q2 2026. On a quarterly growth basis, Beam Therapeutics Inc. Common Stock has generated -98.46% fall in its revenue since last 3-months.
Beam Therapeutics Inc. Common Stock’s net profit fell -19.93% since last year same period to $-122.68Mn in the Q2 2026. On a quarterly growth basis, Beam Therapeutics Inc. Common Stock has generated -30.07% fall in its net profits since last 3-months.
Beam Therapeutics Inc. Common Stock’s net profit margin fell -1972.1% since last year same period to -25036.33% in the Q2 2026. On a quarterly growth basis, Beam Therapeutics Inc. Common Stock has generated -8324.72% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -1.16 |
EPS Estimate Current Year | -1.16 |
Beam Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.16 - a -216% fall from last quarter’s estimates.
Beam Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.16.
Key Ratios
Earning Per Share (EPS) | -1.18 |
Beam Therapeutics Inc. Common Stock’s earning per share (EPS) fell -18% since last year same period to -1.18 in the Q2 2026. This indicates that the Beam Therapeutics Inc. Common Stock has generated -18% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-04 | 1 | -1.18 | -218% |
2026-05-07 | -1.01 | -0.91 | 9.9% |
